Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: A retrospective study and laboratory analysis of the isolates

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 1074-1077

  Lee, Chen Hsiang ^a,b   Su, Lin Hui ^a,b   Tang, Ya Fen ^b   Liu, Jien Wei ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Clinical outcome; In vitro activity; Inoculum effect

Indexed keywords

BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; FLOMOXEF;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTEREMIA; BIOSYNTHESIS; CHILD; DRUG EFFECT; ENTEROBACTER INFECTION; ENZYMOLOGY; FEMALE; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA PNEUMONIAE; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BETA-LACTAMASES; CARBAPENEMS; CEPHALOSPORINS; CHILD; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33845875065     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl381     Document Type: Article

References (10)

1. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657-86.
2. Paterson DL, Ko WC, Von Gottberg A et al. Antibiotic therapy for Klebsiella pneumoniae bacteraemia: Implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2004; 39: 31-7.
3. Go ES, Urban C, Burns J et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994; 344: 1329-32.
4. Jacoby GA, Carreras I. Activities of β-lactam antibiotics against Escherichia coli strains producing extended spectrum β-lactamases. Antimicrob Agents Chemother 1990; 34: 858-62.
5. Lee CH, Su LH, Chia JH et al. Recurrent Klebsiella pneumoniae mycotic aneurysm in a diabetic patient and emergence of an extendedspectrum β-lactamase (CTX-M-24)-containing Klebsiella pneumoniae strain after prolonged treatment with first-generation cephalosporins for mycotic aneurysm. Microb Drug Resist 2004; 10: 359-63.
6. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing - Eleventh Informational Supplements: Approved Standard M100-S10: NCCLS, Villanova, PA, USA, 2001.
7. Grimm H. Interpretive criteria of antimicrobial disk susceptibility tests with flomoxef. Infection 1991; 19 Suppl 5: S258-63.
8. Burgess DS, Hall RG,II. In vitro killing of parenteral β-lactams against standard and high inocula of extended-spectrum β-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2004; 49: 41-6.
9. Andrassy K, Koderisch J, Gorges K et al. Pharmacokinetics and hemostasis following administration of a new, injectable oxacephem (6315-S, flomoxef) in volunteers and in patients with renal insufficiency. Infection 1991; 19 Suppl 5: S296-302.
10. Pangon B, Bizet C, Bure A et al. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 β-lactamase. J Infect Dis 1989; 159: 1005-6.